X

Trial Profile

A double-blind, randomized, placebo-controlled study of atorvastatin as prevention of cerebrovascular events in patients with a previous transient ischemic attack (TIA) or stroke

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 23 May 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atorvastatin (Primary)
Indications Atrial fibrillation; Coronary disorders; Stroke; Transient ischaemic attacks
Focus Therapeutic Use
Acronyms SPARCL
Sponsors Pfizer

Most Recent Events

30 Mar 2020 Results presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology
07 Nov 2017 Results of the biomarker analysis published in the Stroke
17 Jan 2017 Results of biomarker substudy along with main study published in the Journal of the American College of Cardiology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com